Investor Relations

A man with his arms crossed


POINT has built a platform to accelerate the next-generation of radiopharmaceuticals with an industry-leading pipeline, in-house manufacturing capabilities, and redundant supply of rare medical isotopes. The management team brings decades of combined experience in radiopharmaceutical clinical development and manufacturing, including 40+ clinical trials, 12 drug approvals, and 8 GMP radiopharmaceutical facilities, and has leveraged prior relationships to assemble one of the industry’s most resilient radioisotope supply chains. The company’s 100%-owned, 80,000 sq ft facility has capacity to commercially supply both North America and Europe for large volume indications. POINT has two late-stage programs one of which is PNT2002, currently being evaluated in the Phase 3 SPLASH study targeting mCRPC, which could lay the cornerstones of the company’s radiopharmaceutical platform. POINT also has an exciting early-stage pipeline which includes a best-in-class FAP-α targeted radioligand PNT2004, a potential pan-cancer target.
Press Release
29 Nov

POINT Biopharma Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Combining 177Lu-PNT6555 with anti-PD-1 immunotherapy resulted in a significantly increased survival benefit compared to independent treatments in an anti-PD-1 resistant preclinical tumor model. 177Lu-PNT6555, the lead of the PNT2004 pan-cancer fibroblast activation protein-α (FAP-α) targeted program, is currently in a phase 1 trial.

Press Release
14 Nov

POINT Biopharma Reports Third Quarter 2022 Financial Results and Announces Strategic Collaboration and Exclusive License Agreements with Lantheus Holdings

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc. (NASDAQ: LNTH) for the commercialization of PNT2002 & PNT2003.

Events Calendar


~November 14: Q3 2022 Financial Results

November 15: Jefferies London Healthcare Conference
- Format: Company Presentation and 1x1 Meetings
- Webcast link available here

November 29: Piper Sandler 34th Annual Healthcare Conference
- Format: Fireside Chat‍

November 30: EvercoreISI HealthCONx Conference
- Format: 1x1 Meetings


Stock, Financials & Governance

Financial Reports
Board of Directors
Stock Price
SEC Filings
Section 16 Filings

Governance Documents
Audit Committee Charter
Code of Business Conduct and Ethics
Whistleblower Line Information
Compensation Committee Charter
Corporate Governance Guidelines
Nominating and Corporate Governance Committee Charter

Analyst Coverage
Berenberg - Zhiqiang Shu
Brookline - Kemp Dolliver
Cowen - Boris Peaker
Guggenheim - Charles Zhu
Jefferies - Suji Jeong
JonesTrading - Justin Walsh
Oppenheimer - Jeff Jones
Piper Sandler - Ted Tenthoff
Truist - Nicole Germino
William Blair - Andy Hsieh

Please note, this list of analyst coverage may not complete or up to date. Any opinions, estimates or forecasts regarding performance made by analysts do not represent POINT Biopharma or its management team.



1-833-544-2637 x800

Please do not submit any private or confidential information using this form. Fields marked with an asterisk (*) are required.

Thank you!
Your submission has been received!
Oops! Something went wrong while submitting the form.